A5010994282- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Blood Coagulation and Thrombosis Mechanisms
- Hemophilia Treatment and Research
- Lymphoma Diagnosis and Treatment
- Platelet Disorders and Treatments
- Cancer Treatment and Pharmacology
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Vitamin K Research Studies
- Hematopoietic Stem Cell Transplantation
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Vitamin C and Antioxidants Research
- Lung Cancer Treatments and Mutations
- Hepatitis B Virus Studies
- Viral-associated cancers and disorders
- Vascular Tumors and Angiosarcomas
- Hepatitis C virus research
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Lung Cancer Research Studies
Toyohashi Municipal Hospital
2015-2024
Toyohashi Heart Center
2023
Kyowa Kirin (Japan)
2017
Nagoya University Hospital
2017
Boehringer Ingelheim (Canada)
2017
Kyowa Hakko Kirin (Singapore)
2017
Gunma University
2011
Nihon University
2005
Mie University
2005
Kanagawa Prefectural Hospital Organization
2005
A novel therapeutic approach is urgently needed for BCR-ABL-positive acute lymphoblastic leukemia (ALL). In this study, we assessed the efficacy and feasibility of chemotherapy combined with imatinib.A phase II study imatinib-combined was conducted newly diagnosed ALL in adults. Eighty patients were entered into trial between September 2002 January 2005.Remission induction therapy resulted complete remission (CR) 77 (96.2%), resistant disease one patient, early death two patients, as well...
Background. There is no standard management of reactivation hepatitis B virus (HBV) infection in HBV-resolved patients without surface antigen (HBsAg), but with antibodies against core and/or HBsAg (anti-HBs). Methods. We conducted a prospective observational study to evaluate the occurrence HBV by serial monthly monitoring DNA and establish preemptive therapy guided this B-cell non-Hodgkin lymphoma (B-NHL) treated rituximab plus corticosteroid-containing chemotherapy (R-steroid-chemo). The...
Key Points KIT exon 17 mutation is a poor prognostic factor in AML patients with RUNX1-RUNX1T1, but not those CBFB-MYH11. NRAS
Summary The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia (Ph+ ALL) treated imatinib‐combined chemotherapy. Here we report the results prospective MRD monitoring 100 adult patients. Three hundred and sixty‐seven follow‐up bone marrow samples, collected at predefined time points during a uniform treatment protocol, were analysed for BCR‐ABL1 transcripts by quantitative reverse transcription...
Abstract This study aimed to investigate the usefulness of allogeneic stem cell transplantation (allo‐SCT) for Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) in first complete remission (CR1) with molecular (CMR). We compared outcomes between Ph+ALL patients who did or not undergo allo‐SCT CR1. included enrolled prospective clinical studies tyrosine kinase inhibitor era conducted by Japan Adult Leukemia Study Group, achieved CMR within 3 months. A total 147 (allo‐SCT:...
To identify factors associated with relapse-free survival (RFS), 80 patients newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up surviving was 26.7 months (maximum, 52.5 months). Twenty-eight out 77 who had achieved CR relapsed. probability RFS 50.5% at 2 years. Multivariate analysis revealed that the presence secondary chromosome aberrations addition to t(9;22)...
The Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 study reported a high complete remission (CR) rate for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients treated with imatinib-combined chemotherapy. However, the long-term treatment efficacy remains uncertain. Here, we report final analysis of JALSG study. outcomes were compared those ALL93 and ALL97 studies, which conducted in pre-imatinib era. Ninety-nine newly diagnosed Ph+ALL enrolled (median age, 45...
Abstract The standard treatment for adults with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) in Japan is imatinib-based chemotherapy followed by allogeneic hematopoietic stem cell transplantation (HSCT). However, ∼40% of patients cannot undergo HSCT their first complete remission (CR1) because chemotherapy-related toxicities or relapse before older age. In this study, we evaluated dasatinib-based 2-step induction the primary end point 3-year event-free survival...
Pharmacokinetic (PK) factors have been suggested to be involved in the unfavorable clinical responses of chronic myeloid leukemia (CML) patients treated with imatinib. The purpose this study was clarify prognostic implications PK CML plasma trough (C min ) level imatinib and serum α 1 ‐acid glycoprotein (AGP) were measured on two different days 65 for more than 12 months. We further examined whether C actually reflects inhibitory activity against BCR–ABL kinase using (PIA) assay. Since...
Abstract This study investigated the efficacy of imatinib based therapy with intensified consolidation in patients Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial imatinib‐combined chemotherapy for newly diagnosed BCR‐ABL‐positive ALL adults. Sixty‐eight were included between October 2008 and December 2010. The median age was 49 years, 28 >55 years age. Sixty‐five achieved CR (95.6%). estimated 2‐year...
The vitamin K-dependent carboxylase, a constituent of the endoplasmic reticulum membrane, catalyzes conversion reduced K to epoxide and concomitant glutamic acid γ-carboxyglutamic acid. To study structure-function relationships in enzyme, seventeen clusters charged residues bovine γ-glutamyl carboxylase were substituted with alanines using site-specific mutagenesis. Wild-type mutant species expressed Chinese hamster ovary cells an immunodetectable octapeptide inserted at their amino-terminal...
Recently, various blood cell lineages expressing the BCR-ABL fusion gene in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported. However, biological and clinical significance of these has not established; therefore, we aimed to clarify impacts different BCR-ABL-expressing lineages.Multi-lineage expression (multi-Ph) was defined as outside B-lineage compartment, determined by fluorescence situ hybridization (FISH) peripheral neutrophils bone marrow...
The vitamin K-dependent γ-glutamyl carboxylase catalyzes the posttranslational conversion of glutamic acid to γ-carboxyglutamic in precursor proteins containing γ-carboxylation recognition site (γ-CRS). During this reaction, is converted while KH 2 K 2,3-epoxide. Recombinant bovine was purified free γ-CRS-containing propeptide and endogenous substrate a single-step immunoaffinity procedure. We show that absence and/or glutamate-containing substrate, has little or no epoxidase activity....
Prognostic assessment is crucial for the management of AML. Although use karyotype analysis risk-stratification widely accepted, prognosis AML remains ambiguous, particularly patients categorized into intermediate cytogenetic risk group and additional markers are required an accurate prediction outcome. For this study, we used multiplex real-time RT-PCR, which can simultaneously quantify WT1 10 distinct fusion gene transcripts, to prospectively evaluate pre-treatment bone marrow findings 53...